Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019602HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10018253HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10005829HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10005828HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10033234HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10036190HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10019936HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10020135HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10042400HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TVIS10062547HBVENSG00000198785.7protein_codingGRIN3ANoNo116443Q8TCU5
TCGA Plot Options
Drug Information
GeneGRIN3A
DrugBank IDDB00915
Drug NameAmantadine
Target IDBE0000641
UniProt IDQ8TCU5
Regulation Typeantagonist
PubMed IDs15800186; 10443547
CitationsBlanpied TA, Clarke RJ, Johnson JW: Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005 Mar 30;25(13):3312-22.@@Hesselink MB, De Boer AG, Breimer DD, Danysz W: Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. J Neural Transm (Vienna). 1999;106(5-6):409-21.
GroupsApproved
Direct ClassificationMonoalkylamines
SMILESNC12CC3CC(CC(C3)C1)C2
Pathways
PharmGKBPA448360
ChEMBLCHEMBL660